Sobi’s $1.5 billion takeover of Arthrosi at the end of 2025 has started to pay off, with a positive phase 3 trial for gout therapy pozdeutinurad.
Roche launches liver disease algorithm panel
Roche has introduced what it says is the first comprehensive panel of certified algorithms to help manage people living with chronic liver disease.